Table 2.
Individual Characteristics and Mobilization Parameters in Plerixafor-Mobilized Patients
| Patient no. | Age (years) | Weight (kg) | Sex | Splenectomy | WBCs baseline (×103/μl) | Max WBCs (×103/μl) | Max blood CD34+ (cells/μl) | CD34+ cell yield (×106/kg) | No. of aphereses |
|---|---|---|---|---|---|---|---|---|---|
| P01 | 29 | 63 | M | N | 5.30 | 18.30 | 44 | 7.05 | 2 |
| P02 | 28 | 57 | M | Y | 16.47 | 61.40 | 220 | 9.32 | 1 |
| P03 | 23 | 70 | M | Y | 10.60 | 33.00 | 62 | 6.00 | 2 |
| P05 | 42 | 61 | F | Y | 10.30 | 34.00 | 72 | 8.92 | 2 |
| P06 | 34 | 71 | M | Y | 13.80 | 54.50 | 78 | 7.19 | 2 |
| P07 | 39 | 58 | F | N | 5.50 | 18.00 | 57 | 7.28 | 2 |
| P08 | 37 | 69 | M | N | 7.80 | 25.60 | 51 | 7.28 | 2 |
| P09 | 38 | 64 | M | N | 5.80 | 18.00 | 30 | 4.32 | 2 |
| P10 | 42 | 85 | M | Y | 8.50 | 40.00 | 66 | n/a | 2 |
| P11 | 38 | 76 | M | Y | 9.67 | 32.20 | 40 | 4.50 | 2 |
| P12 | 29 | 68 | M | N | 6.74 | 20.80 | 87 | 5.74 | 2 |
| P13 | 25 | 67 | F | N | 7.26 | 22.80 | 18 | 2.53 | 2 |
| P14 | 40 | 73 | M | Y | 5.90 | 15.18 | 61 | 7.81 | 2 |
| P15 | 31 | 51 | F | N | 6.40 | 18.60 | 31 | n/a | 2 |
| P16 | 25 | 50 | F | N | 5.69 | 22.85 | 24 | 5.10 | 2 |
| P17 | 26 | 61 | M | Y | 8.39 | 26.90 | 16 | 1.26 | 2 |
| P18 | 23 | 76 | M | Y | 11.05 | 43.30 | 126 | 6.68 | 1 |
| P19 | 32 | 56 | M | Y | 14.80 | 48.76 | 76 | 6.51 | 2 |
| P20 | 40 | 74 | M | Y | 21.00 | 37.80 | 80 | 9.14 | 2 |
P01–P10 have previously been reported in the study's interim analysis (Yannaki et al., 2012). P10 was initially considered as plerixafor mobilization failure; however, it was later recognized that poor CD34+ collection was because of technical failure during aphereses. P04 is not included because she received only G-CSF+plerixafor in this study, because of previous G-CSF mobilization failure. P11, P13, and P17 were later remobilized with G-CSF+plerixafor. n/a, not applicable (refers to nonevaluable patients described in the Results section). F, female; M, male; N, no; Y, yes.